Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|24|4284-4289

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.24, 2013-12, pp. : 4284-4289

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and Tolerability of Pegylated Interferon-α_2a plus Ribavirin versus Pegylated Interferon-α_2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients

Intervirology, Vol. 53, Iss. 3, 2010-01 ,pp. : 146-153

Karger

Access to resources Recommend Favorite

Changes in Expression of Apoptosis-Related Genes Are Linked to the Molecular Response to Imatinib Treatment in Chronic-Phase Chronic Myeloid Leukemia Patients

Acta Haematologica, Vol. 117, Iss. 2, 2006-11 ,pp. : 83-90

Karger

Access to resources Recommend Favorite

Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long‐term 9‐year follow‐up of 134 patients

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : E95-E96

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C

International Journal of Molecular Medicine, Vol. 30, Iss. 5, 2012-01 ,pp. : 1048-1052

Spandidos Publications

Access to resources Recommend Favorite

Neutralizing anti‐interferon‐α antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (α2a) and lymphoblastoid interferon‐α

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 2, 1996-08 ,pp. : 300-305

John Wiley & Sons Inc

Access to resources Recommend Favorite